| Primary |
| Breast Cancer |
34.0% |
| Breast Cancer Metastatic |
13.9% |
| Gastric Cancer |
13.5% |
| Her-2 Positive Breast Cancer |
5.1% |
| Prophylaxis |
4.7% |
| Product Used For Unknown Indication |
4.6% |
| Vomiting |
3.7% |
| Nausea |
2.9% |
| Drug Use For Unknown Indication |
2.8% |
| Diarrhoea |
1.8% |
| Hypertension |
1.7% |
| Pain |
1.7% |
| Premedication |
1.5% |
| Stomatitis |
1.5% |
| Supportive Care |
1.5% |
| Pain Prophylaxis |
1.2% |
| Hypersensitivity |
1.1% |
| International Normalised Ratio Increased |
0.9% |
| Metastases To Bone |
0.9% |
| Pyrexia |
0.9% |
|
| Disease Progression |
19.8% |
| Pulmonary Embolism |
8.1% |
| Pneumonia |
7.0% |
| Vomiting |
7.0% |
| Ejection Fraction Decreased |
5.8% |
| Renal Failure Acute |
5.8% |
| Thrombocytopenia |
5.8% |
| Death |
3.5% |
| Enteritis |
3.5% |
| Fatigue |
3.5% |
| Febrile Neutropenia |
3.5% |
| Mucosal Inflammation |
3.5% |
| N-terminal Prohormone Brain Natriuretic Peptide Increased |
3.5% |
| Pleural Effusion |
3.5% |
| Pyrexia |
3.5% |
| Vision Blurred |
3.5% |
| Abdominal Pain |
2.3% |
| Caecitis |
2.3% |
| Cellulitis |
2.3% |
| Clostridium Difficile Colitis |
2.3% |
|
| Secondary |
| Breast Cancer |
39.8% |
| Her-2 Positive Breast Cancer |
12.6% |
| Product Used For Unknown Indication |
10.8% |
| Breast Cancer Metastatic |
9.8% |
| Drug Use For Unknown Indication |
5.2% |
| Malignant Breast Neoplasm |
4.3% |
| Nausea |
2.4% |
| Non-small Cell Lung Cancer |
2.1% |
| Pain |
1.8% |
| Prophylaxis |
1.8% |
| Gastric Cancer |
1.5% |
| Premedication |
1.5% |
| Neuroendocrine Carcinoma |
1.1% |
| Diarrhoea |
1.1% |
| Stomatitis |
0.9% |
| Hypertension |
0.8% |
| Vomiting |
0.7% |
| Prophylaxis Of Nausea And Vomiting |
0.6% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
0.6% |
| Anxiety |
0.5% |
|
| Left Ventricular Dysfunction |
8.5% |
| Febrile Neutropenia |
7.0% |
| Disease Progression |
6.1% |
| Hepatitis Fulminant |
6.1% |
| Pneumonia |
6.1% |
| Pulmonary Embolism |
5.6% |
| Pyrexia |
5.6% |
| Nausea |
5.2% |
| Urinary Tract Infection |
5.2% |
| Vomiting |
5.2% |
| Diarrhoea |
4.7% |
| Skin Infection |
4.7% |
| Hypokalaemia |
4.2% |
| Calculus Ureteric |
3.8% |
| Death |
3.8% |
| Dehydration |
3.8% |
| Haemoptysis |
3.8% |
| Neutropenia |
3.8% |
| Osmotic Demyelination Syndrome |
3.8% |
| Atrial Fibrillation |
3.3% |
|
| Concomitant |
| Breast Cancer |
43.8% |
| Her-2 Positive Breast Cancer |
18.2% |
| Product Used For Unknown Indication |
17.0% |
| Breast Cancer Metastatic |
8.0% |
| Prophylaxis |
4.0% |
| Neoplasm Malignant |
2.3% |
| Metastases To Liver |
1.7% |
| Chemotherapy |
1.1% |
| Hormone Therapy |
1.1% |
| Hypersensitivity |
1.1% |
| Metastases To Central Nervous System |
1.1% |
| Nausea |
0.6% |
|
| Neutropenic Sepsis |
34.3% |
| Skin Infection |
11.4% |
| Colitis |
5.7% |
| Febrile Neutropenia |
5.7% |
| Pleural Effusion |
5.7% |
| Sepsis |
5.7% |
| Circulatory Collapse |
2.9% |
| Diarrhoea |
2.9% |
| Dihydropyrimidine Dehydrogenase Deficiency |
2.9% |
| Hepatitis |
2.9% |
| Nausea |
2.9% |
| Onycholysis |
2.9% |
| Scleroderma |
2.9% |
| Staphylococcus Test Positive |
2.9% |
| Syncope |
2.9% |
| Thrombocytopenia |
2.9% |
| Treatment Failure |
2.9% |
|
